Raymond James Financial
RGNX icon

Raymond James Financial’s Regenxbio RGNX Stock Holding History

Raymond James Financial’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$848K Buy
101,245
+15,244
+18% +$160K ﹤0.01% 3974
2025
Q4 		$1.24M Sell
86,001
-9,277
-10% -$116K ﹤0.01% 3639
2025
Q3 		$919K Sell
95,278
-16,219
-15% -$143K ﹤0.01% 3734
2025
Q2 		$915K Buy
111,497
+12,115
+12% +$101K ﹤0.01% 3645
2025
Q1 		$711K Buy
99,382
+25,872
+35% +$192K ﹤0.01% 3712
2024
Q4 		$568K Buy
+73,510
New +$690K ﹤0.01% 3830

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's RGNX Position: Q1 2026 in Review

Raymond James Financial increased its Regenxbio (RGNX) stake by 18% in Q1 2026, buying an estimated $160K and bringing the position to 101,245 shares worth $848K. The position accounts for ﹤0.01% of the portfolio, ranked #3974.

Raymond James Financial first reported a position in RGNX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.24M in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Raymond James Financial held 101,245 shares of Regenxbio worth $848K as of Q1 2026.
  • Raymond James Financial bought 15,244 Regenxbio shares in Q1 2026, an estimated $160K.
  • Regenxbio made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3974 holding.
  • Raymond James Financial first reported a position in Regenxbio in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Regenxbio position peaked at $1.24M in Q4 2025.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.